Back close

Dr. Sreeja Roy

Associate Professor, Amrita Research Center, Amrita Vishwa Vidyapeetham, Faridabad

Qualification: BSc, MSc, Ph.D

Bio

Dr. Sreeja Roy is an Associate Professor at the Amrita Research Center, Amrita Vishwa Vidyapeetham, Faridabad. She earned her BSc (Hons) in Viral Immunology from the Australian National University (ANU), Canberra, followed by an MSc in Infection Biology from the University of Lübeck, Germany. Her master’s research focused on the therapeutic role of Interleukin-10 in mitigating complement-mediated autoimmunity. Dr. Roy returned to The John Curtin School of Medical Research, ANU, Canberra, to pursue a PhD in mucosal immunology focusing on HIV vaccines. Her doctoral work emphasized the advantages of mucosal vaccines over parenteral vaccines against mucosal pathogens like HIV. She demonstrated that nature of the viral vaccine vector plays a crucial role in influencing mucosal innate lymphoid cell (ILC) and dendritic cell (DC) profiles that ultimately determine the vaccine efficacy. Building on her expertise in mucosal immunology, Dr. Roy completed her first postdoctoral fellowship at Albany Medical College, New York, where she contributed towards the development of an intranasal universal influenza vaccine capable of eliciting cross-protective immunity. In her second postdoctoral fellowship at the Sanford Burnham Prebys Medical Discovery Institute, California, in an effort to consolidate her expertise in chronic viral vaccines, autoimmune therapeutics and host-pathogen interactions, she shifted her focus to translational medicine, investigating immune mechanisms underlying novel immunotherapy strategies for treatment-resistant solid tumors that can complement immune checkpoint blockade therapies for improved patient outcomes.

At Amrita Research Center, Dr. Roy is now focused on developing a site-specific therapeutic cancer vaccine that can circumvent stromal barriers to access and induce lymphoid organisation in the tumor microenvironment for effective tumor growth regression.

Publications

Journal Article

Year : 2023

PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion

Cite this Research Publication : Hope, J.L., Otero, D., Bae, E., Stairiker, C.J., Palete, A.B., Faso, H.A., Lin, M., Henriquez, M.L., Roy, S., Seo, H., Lei, X., Wang, E.S., Chow, S., Tinoco, R., Daniels, G.A., Yip, K., Campos, A.R., Yin, J., Adams, P.D., Rao, A., and Bradley, L.M. PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion. Cell Reports. 2023

Publisher : Cell Reports

Year : 2022

Lung group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza

Cite this Research Publication : Williams, C.M., Roy, S., Sun, W., Furuya, A.M., Wijesundara, D.K., Furuya, Y. Lung group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza. Clin Trans Immunol. 2022

Publisher : Clin Trans Immunol

Year : 2022

Evaluation of Innate Lymphoid Cells and Dendritic Cells Following Viral Vector Vaccination. In: Brun, A. (eds) Vaccine Technologies for Veterinary Viral Diseases

Cite this Research Publication : Li, Z., Roy, S., and Ranasinghe, C. (2022). Evaluation of Innate Lymphoid Cells and Dendritic Cells Following Viral Vector Vaccination. In: Brun, A. (eds) Vaccine Technologies for Veterinary Viral Diseases. Methods in Molecular Biology, vol 2465. Humana, New York, NY

Publisher : Humana

Year : 2021

IL-13Rα2 Regulates the IL-13/IFN-γ Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination

Cite this Research Publication : Li, Z., Roy, S., and Ranasinghe, C. IL-13Rα2 Regulates the IL-13/IFN-γ Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination. Vaccines. 2021

Publisher : Vaccines

Year : 2021

STAT3 determines IL-4 signalling outcomes in naïve T cells

Cite this Research Publication : Deimel, L.P., Li, Z., Roy, S.,and Ranasinghe, C. STAT3 determines IL-4 signalling outcomes in naïve T cells.Scientific Reports. 2021

Publisher : Scientific Reports

Year : 2021

Detrimental impact of allergic airway disease on live attenuated influenza vaccine

Cite this Research Publication : Roy, S., Williams, C.M., and Furuya, Y. Detrimental impact of allergic airway disease on live attenuated influenza vaccine. Health Science Reports. 2021

Publisher : Health Science Reports

Year : 2021

IL-33-ILC2 axis represents a potential adjuvant target to increase the cross-protective efficacy of influenza vaccine

Cite this Research Publication : Williams, C.M., Roy, S., Califano, D., McKenzie, A.N.J., Metzger, D.W., and Furuya,Y. IL-33-ILC2 axis represents a potential adjuvant target to increase the cross-protective efficacy of influenza vaccine. J. Virol. 2021

Publisher : J. Virol.

Year : 2020

A Triple-challenge Mouse Model of Allergic Airway Disease, Primary Influenza Infection, and Secondary Bacterial Infection

Cite this Research Publication : Roberts, S., Williams M.C., Roy, S*., Furuya, Y. A Triple-challenge Mouse Model of Allergic Airway Disease, Primary Influenza Infection, and Secondary Bacterial Infection. Bio-Protocol 2020

Publisher : Bio-Protocol

Year : 2020

Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity

Cite this Research Publication : Roy, S., Williams, M.C., Pardo, J., Wijesundara, D.K., and Furuya, Y. Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity. Vaccines 2020

Publisher : Vaccines

Year : 2020

Impact of pre-existing immunity to influenza on live attenuated influenza vaccine (LAIV) immunogenicity

Cite this Research Publication : Roy, S.,Williams, M.C., Wijesundara, D.K., and Furuya, Y. Impact of pre-existing immunity to influenza on live attenuated influenza vaccine (LAIV) immunogenicity. Vaccines 2020

Publisher : Vaccines

Year : 2020

Unique IL-13Rα2/STAT3 mediated IL-13 regulation detected in lung conventional dendritic cells, 24 h post viral vector vaccination

Cite this Research Publication : Roy, S., Liu, H., Jaeson, M.I., Deimel, L.P., and Ranasinghe, C. Unique IL-13Rα2/STAT3 mediated IL-13 regulation detected in lung conventional dendritic cells, 24 h post viral vector vaccination. Scientific Reports2020

Publisher : Scientific Reports

Year : 2019

Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes

Cite this Research Publication : Roy, S., Mahboob, S., Li, Z., Jaeson, M.I., Jackson, J.R., Grubor-Bauk, B., Wijesundara, D.K., Gowans E.J., and Ranasinghe, C. Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. Vaccine 2019

Publisher : Vaccine

Year : 2018

Unexpected Involvement of IL-13 Signalling via a STAT6 Independent Mechanism, During IgG2a Development Following Viral Vaccination

Cite this Research Publication : Hamid, M.A.*, Jackson, J.R.*, Roy, S*, Khanna, M., and Ranasinghe, C. Unexpected Involvement of IL-13 Signalling via a STAT6 Independent Mechanism, During IgG2a Development Following Viral Vaccination. Eur J Immunol. 2018

Publisher : Eur J Immunol

Year : 2015

Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse

Cite this Research Publication : Karsten, C.M., Laumonnier, Y., Eurich, B., Ender, F., Bröker, K., Roy, S., Czabanska, A., Vollbrandt, T., Figge, J., and Köhl, J. Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse. J. Immunol.2015

Publisher : J. Immunol

Book Chapter

Year : 2018

IL-4 and IL-13 Receptors

Cite this Research Publication : Ranasinghe, C., Roy, S., Li, Z., Khanna, M., Jackson, R.J. (2018). IL-4 and IL-13 Receptors. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, Cham

Publisher : Springer

Admissions Apply Now